Drug intelligence / Profile preview

ET-901

Development stage: Phase 2
Lead developer: EdiGene
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ATHENA CAR-T (ET-901) is an allogeneic, universal chimeric antigen receptor T cell (CAR-T) therapy developed by EdiGene. It targets the B-lymphocyte antigen CD19 and is designed for immunologic cytotoxicity and T lymphocyte replacement. The therapy involves knocking out three genes (TRAC and Power3), enabling the use of donor-derived T cells that are less likely to cause graft-versus-host disease. Its primary mechanism of action is modulation of CD19 on B cells, leading to their targeted destruction. ATHENA CAR-T is being investigated for hematologic malignancies such as B-cell lymphoma as well as autoimmune diseases like systemic lupus erythematosus[1][3][4][8].

Other names: ATHENA CD19-directed chimeric antigen receptor -T Cell

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on ET-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ET-901.

Explore the full profile